These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 35219791)

  • 1. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J
    J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
    Lu JC; Zhang PF; Huang XY; Guo XJ; Gao C; Zeng HY; Zheng YM; Wang SW; Cai JB; Sun QM; Shi YH; Zhou J; Ke AW; Shi GM; Fan J
    J Hematol Oncol; 2021 Nov; 14(1):200. PubMed ID: 34838121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to: "PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma" [J Hepatol 77 (2022) 163-176].
    Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Cai JB; Ke AW; Fan J
    J Hepatol; 2023 Apr; 78(4):881-882. PubMed ID: 36564318
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
    Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
    Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
    Sun G; Liu H; Zhao J; Zhang J; Huang T; Sun G; Zhao S; Zhang Z; Cao H; Rong D; Kong X; Ji Q; Liu L; Wang X; Tang W; Xia Y
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
    Xie P; Yu M; Zhang B; Yu Q; Zhao Y; Wu M; Jin L; Yan J; Zhou B; Liu S; Li X; Zhou C; Zhu X; Huang C; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Guo L; Li H
    J Hepatol; 2024 Jul; 81(1):93-107. PubMed ID: 38403027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
    Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
    Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
    Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.
    Rong D; Wang Y; Liu L; Cao H; Huang T; Liu H; Hao X; Sun G; Sun G; Zheng Z; Kang J; Xia Y; Chen Z; Tang W; Wang X
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8
    Cai N; Cheng K; Ma Y; Liu S; Tao R; Li Y; Li D; Guo B; Jia W; Liang H; Zhao J; Xia L; Ding ZY; Chen J; Zhang W
    Gut; 2024 May; 73(6):985-999. PubMed ID: 38123979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer.
    Zhu M; Zhang P; Yu S; Tang C; Wang Y; Shen Z; Chen W; Liu T; Cui Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):14. PubMed ID: 34996504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
    Zhou C; Weng J; Liu C; Liu S; Hu Z; Xie X; Gao D; Zhou Q; Sun J; Xu R; Li H; Shen Y; Yi Y; Shi Y; Sheng X; Dong Q; Hung MC; Ren N
    Gastroenterology; 2023 Jun; 164(7):1261-1278. PubMed ID: 36863689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.
    Wang X; Zhou T; Chen X; Wang Y; Ding Y; Tu H; Gao S; Wang H; Tang X; Yang Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody.
    Li Z; Li B; Peng D; Xing H; Wang G; Li P; Wang J; Ye G; Chen J
    Int J Oncol; 2018 Jun; 52(6):2079-2092. PubMed ID: 29620156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
    Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
    He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
    Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.
    Kong X; Zheng Z; Song G; Zhang Z; Liu H; Kang J; Sun G; Sun G; Huang T; Li X; Rong D; Wang K; Tang W; Xia Y
    Front Immunol; 2022; 13():876048. PubMed ID: 35812439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TOX promotes the exhaustion of antitumor CD8
    Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
    J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.